Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase - PubMed (original) (raw)
. 2004 Jan 15;13(2):159-70.
doi: 10.1093/hmg/ddh019. Epub 2003 Nov 25.
Daniel J Fadale, Jeffrey Anderson, Guilian M Xu, Victoria Gonzales, Nancy A Jenkins, Neal G Copeland, Michael K Lee, Linda H Younkin, Steven L Wagner, Steven G Younkin, David R Borchelt
Affiliations
- PMID: 14645205
- DOI: 10.1093/hmg/ddh019
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase
Joanna L Jankowsky et al. Hum Mol Genet. 2004.
Abstract
Amyloid precursor protein (APP) is endoproteolytically processed by BACE1 and gamma-secretase to release amyloid peptides (Abeta40 and 42) that aggregate to form senile plaques in the brains of patients with Alzheimer's disease (AD). The C-terminus of Abeta40/42 is generated by gamma-secretase, whose activity is dependent upon presenilin (PS 1 or 2). Missense mutations in PS1 (and PS2) occur in patients with early-onset familial AD (FAD), and previous studies in transgenic mice and cultured cell models demonstrated that FAD-PS1 variants shift the ratio of Abeta40 : 42 to favor Abeta42. One hypothesis to explain this outcome is that mutant PS alters the specificity of gamma-secretase to favor production of Abeta42 at the expense of Abeta40. To test this hypothesis in vivo, we studied Abeta40 and 42 levels in a series of transgenic mice that co-express the Swedish mutation of APP (APPswe) with two FAD-PS1 variants that differentially accelerate amyloid pathology in the brain. We demonstrate a direct correlation between the concentration of Abeta42 and the rate of amyloid deposition. We further show that the shift in Abeta42 : 40 ratios associated with the expression of FAD-PS1 variants is due to a specific elevation in the steady-state levels of Abeta42, while maintaining a constant level of Abeta40. These data suggest that PS1 variants do not simply alter the preferred cleavage site for gamma-secretase, but rather that they have more complex effects on the regulation of gamma-secretase and its access to substrates.
Similar articles
- Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases.
Mastrangelo P, Mathews PM, Chishti MA, Schmidt SD, Gu Y, Yang J, Mazzella MJ, Coomaraswamy J, Horne P, Strome B, Pelly H, Levesque G, Ebeling C, Jiang Y, Nixon RA, Rozmahel R, Fraser PE, St George-Hyslop P, Carlson GA, Westaway D. Mastrangelo P, et al. Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8972-7. doi: 10.1073/pnas.0500940102. Epub 2005 Jun 10. Proc Natl Acad Sci U S A. 2005. PMID: 15951428 Free PMC article. - Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease.
Steiner H, Capell A, Leimer U, Haass C. Steiner H, et al. Eur Arch Psychiatry Clin Neurosci. 1999;249(6):266-70. doi: 10.1007/s004060050098. Eur Arch Psychiatry Clin Neurosci. 1999. PMID: 10653281 Review. - Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.
Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH, Pietrzik CU, Baumann K, Weggen S. Czirr E, et al. J Biol Chem. 2007 Aug 24;282(34):24504-13. doi: 10.1074/jbc.M700618200. Epub 2007 Jun 15. J Biol Chem. 2007. PMID: 17573346 - Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin [correction of nacastrin], aph-1a, and pen-2.
Zhang L, Lee J, Song L, Sun X, Shen J, Terracina G, Parker EM. Zhang L, et al. Biochemistry. 2005 Mar 22;44(11):4450-7. doi: 10.1021/bi0481500. Biochemistry. 2005. PMID: 15766275 - BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R. Vassar R. J Mol Neurosci. 2004;23(1-2):105-14. doi: 10.1385/JMN:23:1-2:105. J Mol Neurosci. 2004. PMID: 15126696 Review.
Cited by
- Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease.
Joshi G, Wang Y. Joshi G, et al. Bioessays. 2015 Mar;37(3):240-7. doi: 10.1002/bies.201400116. Epub 2014 Dec 28. Bioessays. 2015. PMID: 25546412 Free PMC article. Review. - Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
Johnson ECB, Ho K, Yu GQ, Das M, Sanchez PE, Djukic B, Lopez I, Yu X, Gill M, Zhang W, Paz JT, Palop JJ, Mucke L. Johnson ECB, et al. Mol Neurodegener. 2020 Sep 14;15(1):53. doi: 10.1186/s13024-020-00393-5. Mol Neurodegener. 2020. PMID: 32921309 Free PMC article. - Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo.
Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, Perez R, Mahan TE, Sutphen CL, Holtzman DM. Macauley SL, et al. J Clin Invest. 2015 Jun;125(6):2463-7. doi: 10.1172/JCI79742. Epub 2015 May 4. J Clin Invest. 2015. PMID: 25938784 Free PMC article. - AP39, a Mitochondria-Targeted Hydrogen Sulfide Donor, Supports Cellular Bioenergetics and Protects against Alzheimer's Disease by Preserving Mitochondrial Function in APP/PS1 Mice and Neurons.
Zhao FL, Fang F, Qiao PF, Yan N, Gao D, Yan Y. Zhao FL, et al. Oxid Med Cell Longev. 2016;2016:8360738. doi: 10.1155/2016/8360738. Epub 2016 Jan 31. Oxid Med Cell Longev. 2016. PMID: 27057285 Free PMC article. - Novel Botanical Therapeutic NB-02 Effectively Treats Alzheimer's Neuropathophysiology in an APP/PS1 Mouse Model.
Lee YF, Lariviere L, Russ AN, Choi SZ, Bacskai BJ, Kastanenka KV. Lee YF, et al. eNeuro. 2021 May 24;8(3):ENEURO.0389-20.2021. doi: 10.1523/ENEURO.0389-20.2021. Print 2021 May-Jun. eNeuro. 2021. PMID: 33926907 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases